NASDAQ:CNTX Context Therapeutics Q4 2025 Earnings Results & Report $0.30 +0.01 (+1.74%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.30 -0.01 (-1.71%) As of 10/9/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Context Therapeutics missed analyst earnings expectations in its Q4 2025 results, released March 23, 2026. The company reported EPS of -$0.14 versus the -$0.11 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 23, 2026TimeBefore Market OpensConference Call7:00 AM ET Context Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.11Beat/MissMissed by -$0.03One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersContext Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsContext Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Context Therapeutics Q4 2025 Earnings FAQ Did Context Therapeutics beat earnings estimates for Q4 2025? Context Therapeutics (NASDAQ:CNTX) reported earnings of -$0.14 per share for Q4 2025, missing the consensus estimate of -$0.11. The report was announced on Monday, March 23, 2026. When is Context Therapeutics' next earnings date? Context Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Context Therapeutics on the company's earnings history page. Context Therapeutics Earnings HeadlinesContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 11 at 1:00 AM | InvestorPlace (Ad)Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid TumorsSeptember 9, 2026 | quiverquant.comQContext Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202September 9, 2026 | globenewswire.comLifeSci Capital downgrades Context Therapeutics (CNTX) to a HoldAugust 10, 2026 | theglobeandmail.comSee More Context Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email. Email Address About Context TherapeuticsContext Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines. Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is intended to recruit and activate a patient’s immune system against CLDN6-expressing solid tumors, including certain ovarian, endometrial, testicular, and other cancers. CTIM-76 is being evaluated in early-stage clinical development. Historically, Context also developed onapristone extended release, an investigational oral therapy targeting the progesterone receptor pathway for hormone-driven cancers, including certain forms of breast and gynecologic cancer. The company has since prioritized its CLDN6-focused immuno-oncology platform and continues to advance its pipeline through clinical research and collaborations in the United States and other markets as applicable.View Context Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
